Recruiting

VCFix

Sponsor:

Amber Implants B.V.

Code:

NCT07920484

Conditions

Vertebra Compression Fracture

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

VCFix Spinal System in stand-alone configuration

Study Details

Brief summary:

This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice.

Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use.

The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility.

The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.

Conditions

Vertebra Compression Fracture

Study ID

NCT07920484

Start date

Oct 4, 2026

Status verified date

Nov, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Jul 21, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 1\. Subject is ≥ 21 to ≤ 85 years old. 2.

Single vertebral fracture which meets all of the following criteria:

  • Type A fractures from AO spine classification (compression injuries);
  • Vertebral fracture located in the thoracic and lumbar regions of the spine
  • Fracture age < 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
  • Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
  • Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) < 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion Criteria:

1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
2. Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).
3. Spondylolisthesis > Grade 1 at target vertebral body(s)
4. Local kyphotic angle > 30°
5. Any pre-existing vertebral fracture prior to the index fracture
6. Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture
7. Subjects that require anterior stabilization of the index fracture
8. Fracture to the pedicle based on radiographic evaluation
9. Spinal cord compression or canal compromise requiring decompression
10. Severe back pain due to causes other than acute fracture with NPRS score > 5
11. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
12. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication
13. Pre-existing neurological deficit, radiculopathy or myelopathy
14. Pre-existing condition or significant co-morbidity:

1. Uncontrolled diabetes (HbA1c >8%)
2. Severe cardiopulmonary deficiencies
3. Any other condition that would impact study outcome in the opinion of the investigator
15. Irreversible coagulopathy or bleeding disorder
16. Contraindications to both MRI and Computed Tomography (CT) imaging
17. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study
18. A life expectancy less than the study duration or undergoing palliative care
19. Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure
20. Allergy to any components of the device/instruments used during the procedure
21. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
22. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)
23. Any evidence of alcohol or drug abuse
24. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for >3 months)
25. The subject is currently on anti-cancer therapy or anti-HIV therapy
26. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.
27. Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Implant of the VCFix device per IFU

Patients with a (suspected) diagnosis of severe osteoporosis and a single vertebral compression fracture

Interventions

VCFix Spinal System in stand-alone configuration

The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

Primary outcome measure

  • Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety) [ Time Frame: 1 month ]
  • Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS) [ Time Frame: 6 months ]
  • Functional disability, measured by the Oswestry disability index (ODI) [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Locations

Montefiore Medical Center

Recruiting

New York, New York, United States, 10467

Contacts

Research Administrator

(718) 920-6202

More Information

Sponsor

Amber Implants B.V.

Last update posted

Nov 5, 2026

Last verified

Nov, 2026

Keywords

  • VCF
  • EXPAND-US
  • vertebral stabilization
  • fracture
  • vertebral fracture
  • osteoporosis
  • expandable implant

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-06. This information was provided to ClinicalTrials.gov by Amber Implants B.V. on 2026-11-05. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.